The report “Hemophilia Epidemiology Market Forecast to 2026” provides an overview of the comorbidities and the global and historical trends for hemophilia in seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). The report includes a 10-year epidemiological forecast for the diagnosed prevalent cases of hemophilia segmented by type (hemophilia A and hemophilia B), sex, and age (for all ages) in these markets. The diagnosed prevalent cases of hemophilia A and hemophilia B by severity and with inhibitors were also provided in the report. In the 7MM, epidemiologists forecast an increase in the diagnosed prevalent cases of hemophilia A and hemophilia B, from 51,627 diagnosed prevalent cases in 2016 to 52,566 diagnosed prevalent cases in 2026, with an Annual Growth Rate (AGR) of 0.18% during the forecast period. The US will have the highest number of diagnosed prevalent cases of hemophilia A and hemophilia B among the 7MM throughout the forecast period, while Spain will have the lowest.
Request Sample Report at http://www.reportsnreports.com/contacts/requestsample.aspx?name=1133012
Hemophilia is an X-linked hereditary bleeding disorder, characterized by impaired blood coagulation as a result of deficiencies in the production or function of coagulation factor VIII (FVIII) in hemophilia A or factor IX (FIX) in hemophilia B (Bolton-Maggs and Pasi, 2003). Because of the deficiency of coagulation factor, hemophilia patients have a tendency for bleeding in joints, muscles, soft tissues, and within mucous membranes, which can be either spontaneous or due to internal or external trauma, depending on the severity of the disease (CDC, 2017b; Mayo Clinic, 2014).Among the 7MM in 2016, the UK had the highest age-standardized diagnosed prevalence of hemophilia A in men with 20.36 cases per 100,000 population and in women with 0.60 cases per 100,000 population. The age-standardized diagnosed prevalence of hemophilia A in Germany was lowest in men with 9.61 cases per 100,000 population and in women with 0.28 cases per 100,000 population.
The Hemophilia EpiCast Report provides an overview of the risk factors and global trends of hemophilia in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiology forecast of diagnosed prevalent cases of hemophilia segmented by type (hemophilia A and hemophilia B), sex, and age (for all ages) in these seven markets. The hemophilia epidemiology report is written and developed by Masters- and PhD-level epidemiologists. The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
Purchase this report at http://www.reportsnreports.com/purchase.aspx?name=1133012 .
The Hemophilia EpiCast report will allow you to – Develop business strategies by understanding the trends shaping and driving the global hemophilia market. Quantify patient populations in the global hemophilia market to improve product design, pricing, and launch plans. Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for hemophilia therapeutics in each of the markets covered. Identify the percentage of hemophilia prevalent cases by type.
Table 1: Relationship of Bleeding Severity with Clotting Factor Level.
Table 2: Comorbidities for Hemophilia
Table 3: 7MM, Diagnosed Prevalent Cases of Hemophilia A, Both Sexes, All Ages, N, Selected Years 2016-2026.
Table 4: 7MM, Diagnosed Prevalent Cases of Hemophilia B, Both Sexes, All Ages, N, Selected Years 2016-2026.
Table 5: 7MM, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, Both Sexes, All Ages, N and Selected Years 2016-2026.
ReportsnReports.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.
2nd Floor, Metropole,
Bund Garden Road,
Pune – 411001,
Tel: + 1 888 391 5441